首页> 美国卫生研究院文献>Iranian Journal of Pharmaceutical Research : IJPR >Formulation and In-vitro Characterization of Sustained Release Matrix Type Ocular Timolol Maleate Mini-Tablet
【2h】

Formulation and In-vitro Characterization of Sustained Release Matrix Type Ocular Timolol Maleate Mini-Tablet

机译:缓释基质型马来酸替莫洛尔小型片剂的配制和体外表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this study was preparation and evaluation of sustained release matrix type ocular mini-tablets of timolol maleate, as a potential formulation for the treatment of glaucoma.Following the initial studies on timolol maleate powder, it was formulated into ocular mini-tablets. The polymers investigated in this study included cellulose derivatives (HEC, CMC, EC) and Carbopol 971P. Mannitol was used as the solubilizing agent and magnesium stearate as the lubricant. Mini-tablets were prepared by through mixing of the ingredients, followed by direct compression. All the prepared formulations were evaluated in terms of physicochemical tests, including uniformity of weight, thickness, crushing strength, friability and in-vitro drug release.Four groups of formulations were prepared. The presence of different amounts of cellulose derivatives or Carbopol 971P, alone, was studied in group A formulations. In group B formulations, the effect of adding Carbopol 971P alongside different cellulose derivatives was investigated. Group C formulations were made by including mannitol as the solubilizing agent, alongside Carbopol 971P and a cellulose derivative. In group D formulations, mini-tablets were made using Carbopol 971P, alongside two different cellulose derivative. The selected formulation (C1) contained ethyl cellulose, Carbopol 971P, mannitol and magnesium stearate, which showed almost 100% drug release over 5 h. Based on kinetic studies, this formulation was found to best fit the zero-order model of drug release. However, the Higuchi and Hixson -Crowell models also showed a good fit. Hence, overall, formulation C1 was chosen as the best formulation.
机译:本研究的目的是制备和评价马来酸替莫洛尔缓释基质型眼用微片,作为治疗青光眼的一种潜在制剂。在这项研究中研究的聚合物包括纤维素衍生物(HEC,CMC,EC)和Carbopol 971P。甘露醇用作增溶剂,硬脂酸镁用作润滑剂。通过混合各成分,然后直接压片来制备迷你片剂。对所有制备的制剂进行理化测试,包括重量均匀性,厚度,抗碎强度,脆性和体外药物释放。制备了四组制剂。在A组配方中研究了单独存在不同量的纤维素衍生物或Carbopol 971P的情况。在B组配方中,研究了将Carbopol 971P与不同的纤维素衍生物一起添加的效果。通过包括甘露醇作为增溶剂,Carbopol 971P和纤维素衍生物来制备C组配方。在D组配方中,使用Carbopol 971P和两种不同的纤维素衍生物制成了迷你片剂。选定的制剂(C1)包含乙基纤维素,Carbopol 971P,甘露醇和硬脂酸镁,在5小时内显示几乎100%的药物释放。根据动力学研究,发现该制剂最适合药物释放的零级模型。但是,Higuchi和Hixson -Crowell模型也显示出很好的拟合度。因此,总体而言,配方C1被选为最佳配方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号